Impressive Financial Growth

Novartis AG has announced a remarkable 15% increase in its fourth-quarter net sales for the fiscal year 2024, totaling $13.15 billion. This significant growth highlights the company's strong performance in a competitive pharmaceutical market.

Year-End Financial Highlights

For the entire fiscal year, Novartis achieved net sales of $50.32 billion, marking an 11% increase. The company's net income soared by 39% to $11.94 billion, with earnings per share (EPS) climbing 43% to $5.92. These figures underscore Novartis's robust financial health and its ability to generate substantial shareholder value.

Future Outlook

CEO Vas Narasimhan expressed optimism about the company's future, stating, "Looking ahead, we are focused on executing against our pipeline, including 15 submission-enabling readouts over the coming years and more than 30 assets with the potential to drive differentiated growth over the long term." This forward-looking statement reflects Novartis's commitment to innovation and growth in the pharmaceutical sector.